Biotech Values

[maverick_1]

Zack's Grant Zheng CFA on NWBO http://s1.q4cdn.com/460208960/files/News/2016/August-22-2016_NWBO_Zeng.pdf?utm_content=buffer90269&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

OUTLOOK SUMMARY DATA
Risk Level High,
Type of Stock N/A
Industry Med-Biomed/Gene
Zacks Rank in Industry N/A
NWBO is making multiple progresses in its ongoing Phase III clinical trial of DCVax-L for brain cancer and Phase I/II trial of DCVax-Direct for solid tumors. Phase III of DCVax-L has been enrolling patient in the US, UK, Canada and Germany. Hospital Exemption in Germany is under way and UK is following suit. Encouraging data from Phase I/II study of DCVax- Direct reported and three Phase II combination trials to be initiated soon.

Current valuation is attractive